Hemophilia Clinical Trial
Official title:
Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
Life expectancy of haemophilia patients (specially severe) has dramatically increase in the
last decades, which lead to the apparition of aging diseases such as cardiovascular disease,
with the potential bleeding risk of antiplatelet therapies and anticoagulants.
The primary endpoint of the study is to evaluate this bleeding risk in haemophilia patients
(all severity) with such treatment in comparison to non treated patients, according to the
number of bleeding events in the last year reported by the haemophilia patients under study
treatment (antiplatelet and anticoagulant) in comparison to haemophilia patients free of such
treatment. The main hypothesis is that antiplatelet and anticoagulant therapy can be safely
used in minor haemophilia patients but might lead to increase bleeding risk in other
haemophilia patients.
Secondary endpoint consist in:
- Evaluate the impact of know cardio-vascular risk in haemophilia patients (Odd ratios=OR)
- Evaluate the number of sever bleeding event in patient under study treatments compared
to the control group
- Evaluate the overall consumption of factor VIII or IX supply in patients under study
treatments compared to control group
- Estimate the stenosis relapse risk in haemophilia patients with arterial STENT
- Estimate the embolic risk of haemophilia patients with atrial fibrillation
Population description:
Haemophilia patients (man, all severity)
Age above 50 years, followed during the last 5 years in one of the study centre
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05617209 -
In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
|
||
| Completed |
NCT05039008 -
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
|
N/A | |
| Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
| Unknown status |
NCT02165592 -
Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia
|
N/A | |
| Terminated |
NCT02586012 -
Weight-based Dosing in Hemophilia A
|
Phase 2 | |
| Unknown status |
NCT02433782 -
Myofascial Therapy in Patients With Hemophilic Arthropathy
|
N/A | |
| Completed |
NCT02546622 -
ATHN 2: Factor Switching Study
|
||
| Completed |
NCT02165462 -
Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
|
N/A | |
| Completed |
NCT01232634 -
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
|
Phase 2 | |
| Completed |
NCT05104164 -
Self-myofascial Release in Hemophilic Ankle Arthropathy
|
N/A | |
| Terminated |
NCT01191372 -
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
|
Phase 1 | |
| Completed |
NCT05173129 -
Posture Analysis for Patients With Haemophilia
|
N/A | |
| Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
| Withdrawn |
NCT03996486 -
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
|
Phase 1 | |
| Completed |
NCT03842605 -
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
|
N/A | |
| Completed |
NCT01708564 -
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
|
Phase 1 | |
| Completed |
NCT05549843 -
Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle
|
N/A | |
| Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT05027230 -
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|